<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain><z:mpath ids='MPATH_366'>Neuroendocrine tumors</z:mpath> (NETs) are a <z:hpo ids='HP_0001425'>heterogeneous</z:hpo> group of <z:e sem="disease" ids="C0006826" disease_type="Neoplastic Process" abbrv="">malignancies</z:e> </plain></SENT>
<SENT sid="1" pm="."><plain>Therapeutic options depend on location of the primitive <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumor</z:e>, its expandability, its hormonal symptoms and its differentiation </plain></SENT>
<SENT sid="2" pm="."><plain>Though relatively rare, with an increasing incidence and a high prevalence digestive <z:mpath ids='MPATH_366'>neuroendocrine tumors</z:mpath> (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">DNETs</z:e>) are ranked just behind <z:e sem="disease" ids="C1527249,C0009402" disease_type="Neoplastic Process" abbrv="">colorectal cancer</z:e> as the most common <z:e sem="disease" ids="C0685938" disease_type="Neoplastic Process" abbrv="">digestive cancers</z:e> in developed countries </plain></SENT>
<SENT sid="3" pm="."><plain>Three main therapeutic axes have been individualized in the field of well-differentiated <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">DNETs</z:e> (corresponding to grades 1 and 2 of new WHO classification 2010), firstly, antitumor activity of somatostatin analogs, particularly in <z:hpo ids='HP_0003677'>slowly progressive</z:hpo> metastatic <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">DNETs</z:e> with limited hepatic invasion, secondly, targeting <z:mpath ids='MPATH_177'>angiogenesis</z:mpath> in these hypervascular <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumors</z:e> and thirdly targeting the mTOR pathway involved in <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">DNETs</z:e> <z:e sem="disease" ids="C0596263" disease_type="Neoplastic Process" abbrv="">carcinogenesis</z:e> </plain></SENT>
<SENT sid="4" pm="."><plain>As a consequence of two major randomized phase III trials in 2011, <z:chebi fb="0" ids="38940">sunitinib</z:chebi> and everolimus have been considered as new therapeutic options for well-differentiated, advanced and progressive pancreatic NETs </plain></SENT>
<SENT sid="5" pm="."><plain>For everolimus, another phase III study, although non-significant with the chosen criteria, showed effectiveness notably against small intestine NETs </plain></SENT>
<SENT sid="6" pm="."><plain>These targeted therapies are new therapeutic weapons in management of well-differentiated <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">DNETs</z:e>, but its exact role in care strategy, in comparison with other treatments (somatostatin analogs, chemo-embolization, chemotherapyâ€¦) deserves to be precise in the future </plain></SENT>
</text></document>